诺瓦瓦克斯医药盘前直线拉升，新冠疫苗上市事宜有新进展
周三，诺瓦瓦克斯医药盘前直线拉升，截至发稿大涨13%，公司称FDA在批准其新冠疫苗后要求提供额外数据。
根据诺瓦瓦克斯医药的声明，FDA已要求公司承诺在其新冠疫苗获得批准后提供更多临床数据。尽管FDA本月早些时候错过了对该公司基于蛋白质的疫苗作出传统批准决定的最后期限，但诺瓦瓦克斯表示，基于与FDA的对话，公司认为其上市申请"可以批准"。这一消息增强了投资者对公司疫苗最终获批的信心。
值得注意的是，诺瓦瓦克斯医药的这一突破性进展来之不易。该公司今年以来股价累计下跌超过20%，此次利好消息为其股价带来了强劲反弹。市场分析人士认为，如果诺瓦瓦克斯的新冠疫苗最终获得FDA的批准，将对公司未来的业务发展和市场地位产生积极影响。投资者将密切关注FDA的后续决定及诺瓦瓦克斯提供额外临床数据的进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10